3.24
+0.22
(7.28%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 3.02 - 3.32 |
| 52 week | 1.89 - 3.63 |
| Open | 3.10 |
| Vol / Avg. | 982,696.00/251,271.00 |
| Mkt cap | 98.31M |
| P/E | - |
| Div/yield | - |
| EPS | -0.93 |
| Shares | 30.34M |
| Beta | 1.84 |
| Inst. own | 5% |
Events
May 10, 2013
Q1 2013 NexMed Earnings Conference Call
May 6, 2013
Q1 2013 NexMed Earnings Release
Apr 24, 2013
NexMed at Biotechnology Industry Organization (BIO) International Convention
Mar 18, 2013
Apricus Biosciences Inc at Roth Conference
Mar 18, 2013
Q4 2012 Apricus Biosciences Inc Earnings Conference Call
Mar 13, 2013
Apricus Biosciences Inc at EBD BIO-Europe Spring
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -568.15% | -303.71% |
| Operating margin | -519.72% | -295.79% |
| EBITD margin | - | -165.01% |
| Return on average assets | -163.07% | -126.24% |
| Return on average equity | -349.45% | -446.89% |
| Employees | 114 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 300, 11975 El Camino Real
SAN DIEGO, CA 92130
United States - Map
+1-858-2228041 (Phone)
+1-858-5872131 (Fax)
SAN DIEGO, CA 92130
United States - Map
+1-858-2228041 (Phone)
+1-858-5872131 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Apricus Biosciences, Inc. is in the pharmaceutical industry primarily focusing on research and development using its drug delivery technology called NexACT. The Company is actively engaged in acquiring companies and in-licensing drugs that will complement its product portfolio.The Company's pipeline of approved and late stage NexACT based product candidates includes Vitaros, which is approved in Canada for the treatment of erectile dysfunction, Femprox for female sexual arousal disorder, MycoVa for onychomycosis excluding tinea pedis (nail fungal infection), RayVa for Raynaud�s Syndrome and PrevOnco for liver cancer. The Company's pipeline of late stage preclinical products includes Nupen for post-chemotherapy recovery of Neutrophil. In June, 2011, the Company sold Bio-Quant, Inc. (Bio-Quant). On December 29, 2011, the Company acquired Topotarget USA, Inc. In April 2013, the Company announced the sale of Totect (dexrazoxane HCl), and NitroMist (nitroglycerin sublingual aerosol).
Officers and directors
| Rusty Ray | Chairman of the Board | |
| Richard W. Pascoe | Chief Executive Officer, Director | |
| Steven Martin | Chief Financial Officer, Senior Vice President | |
| Randy Berholtz Esq. | Executive Vice President, General Counsel, Secretary | |
| Edward Cox | Vice President - Corporate Development and Investor Relations | |
| Paul V. Maier | Director | |
| Deirdre Y Gillespie M.D. | Independent Director | |
| Leonard A. Oppenheim Esq. | Independent Director | |
| Kleanthis G. Xanthopoulos Ph.D. | Independent Director |